The Board of Starpharma announced the appointment of Dr. Jeff Davies as an independent non-executive director, effective 1 April 2022. Dr. Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at CSL for the Asia-Pacific region, and Global Head of Plasma Product Research and Development at CSL-Behring, Switzerland.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.115 AUD | -.--% | +4.55% | -32.35% |
04-08 | Starpharma, Medicxi Co-Found Petalion Therapeutics; Shares Surge 16% | MT |
03-18 | Starpharma Holdings Limited(ASX:SPL) dropped from S&P/ASX Emerging Companies Index | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-32.35% | 31.49M | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- SPL Stock
- News Starpharma Holdings Limited
- Starpharma Holdings Limited Appoints Jeff Davies as Non-Executive Director, Effective 1 April 2022